Find your way with AssetNav.
Prioritize pipeline assets.
Optimize your resources.
AI and machine learning driving smarter pipeline decisions and strategies.
AssetNav, part of Navigator AI™, is a tool that powers our teams when delivering Asset Prioritization projects. It uses the power of AI and machine learning to help prioritize pipeline assets; supporting commercialization teams to make decisions on how to prioritize their resources and power strategic recommendations.
Powered by people.
Accelerated by AI.
Data and insights are central to what we do. With AssetNav, a product pipeline tool, in our Navigator AI™ suite, our teams can help you to quickly identify and prioritize assets, to power smarter decision-making.
-
Strategic
Smart decisions: Enables real-time strategic decision making, with the ability to rapidly refresh data in the future
Visual insights: Summarized view of data in strategic charts (market, disease, biomarker, asset, trial-level, etc.)
Comparative scores: Comprehensive scoring across various scientific, regulatory and commercial attributes
-
Predictive
AI & ML models: Trained machine learning and artificial intelligence models add ability to predict and interpret key insights from trial data such as anticipated time to market, patient-type categorization, expected line of therapy, and other results
-
Real-time
Deeper insights. Faster: Real time access to pre-structured / merged data from 10+ sources providing instant access to deeper insights, at the touch of a button
Instant filtering: Ability to instantly distil and restructure information or present multiple assets on a prioritized basis.
Impact by numbers.
15+
Data sources covered
50+
Diseases
~20,000
Unique assets
~200,000
Trials
~3,000
Mechanisms of action
17
In-house algorithms
Latest insight.
Using AssetNav to navigate therapeutic landscapes with confidence
We explore two instances where our consulting teams used AssetNav to help clients prioritize promising BD&L opportunities in oncology.
Featured case study.
External opportunity scan in HNSCC
Using Inizio’s proprietary AssetNav tool, we provided information updated in real-time and delivered efficiencies by speeding up the project timeline.
Experts in asset prioritization.
Jo Ann Saitta, Partner, Global Data Strategy, Analytics and AI Practice Lead
Jo Ann helps clients use data, analytics, and AI to solve complex challenges and drive sustainable growth. She defines strategy, value cases, capability readiness, and responsible AI needs to build POCs and MVPs and support implementation at scale.
John L’Ecuyer, Executive Director, Business Development
John helps clients build clinical development and go-to-market strategies across therapy areas. He guides decisions on target profiles, clinical paths, competitive positioning, and opportunity sizing to support early-stage asset prioritization.
Matthew Riordan, Chief Executive Officer & Partner, Putnam
As President of Putnam, Matt leads a team focused on strategic acuity and patient impact. He has partnered with global biopharma across therapeutic areas from pipeline shaping to launch, applying structured thinking and objective analysis to drive results.
Leading the future of Intelligent Commercialization™
We connect data, technology, and AI through an expert-driven, unified framework that enables Intelligent Commercialization™ across every stage of the health and life sciences journey. Our platforms, products, and solutions work together by design to deliver scalable, data-driven impact.
Get in touch.
Let us help you find your way.
